A Lexington company that claims it can make approved drugs and drug candidates safer, more tolerable and more effective has become the fourth Massachusetts biotech company in the past month that intends to go public.
In a filing this week with the U.S. Securities and Exchange Commission, Concert Pharmaceuticals said it intends to raise $74.75 million in an initial public offering on the NASDAQ under the symbol "CNCE," although it did not indicate the number of shares or the price.
In the past month alone, three other local biotechs — Dicerna of Watertown, and Eleven Biotherapeutics and Genocea Biosciences, both of Cambridge — also have filed plans to go public, on the heels of a year that saw nine such companies raise about $885 million in IPOs.
John Sullivan of Leerink Partners said the biotech industry became more attractive to investors after 2012, when the Food and Drug Administration approved 39 new drugs, the largest number in a single year since 1996.
Anda sedang membaca artikel tentang
Concert Pharmaceuticals trumpets plans to go public
Dengan url
http://wartawanlocal.blogspot.com/2014/01/concert-pharmaceuticals-trumpets-plans.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Concert Pharmaceuticals trumpets plans to go public
namun jangan lupa untuk meletakkan link
Concert Pharmaceuticals trumpets plans to go public
sebagai sumbernya
0 komentar:
Posting Komentar